Diabetes drugs may zap precancerous mouth lesions in new trial
NCT ID NCT05727761
First seen Jun 27, 2026 · Last updated Jul 30, 2026 · Updated 2 times
Summary
This study tests whether a combination of two diabetes drugs, pioglitazone and metformin, can shrink or improve precancerous patches in the mouth called oral leukoplakia. About 36 adults with high-risk lesions will take the pills twice daily for 12 weeks. The goal is to see if the treatment reduces the size and severity of the patches and lowers cell growth markers.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ORAL LEUKOPLAKIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
HealthPartners
RECRUITINGSaint Paul, Minnesota, 55130, United States
-
University of Minnesota
RECRUITINGMinneapolis, Minnesota, 55455, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Vitamin a derivative patch could reverse oral precancer
- Can a vitamin d gel or light therapy stop precancerous mouth lesions?
- New light treatment could fight oral cancer without surgery
- Light therapy vs. vitamin d cream: new hope for oral cancer prevention?
- Could a common diabetes drug stop oral cancer before it starts?
- New imaging tool could make mouth biopsies more accurate